BostonGene Named “Overall Immunology Company of the Year” by BioTech Breakthrough for Its AI-Driven Platform That Transforms Immuno-Oncology Drug Development Through Advanced Biomarker Discovery, Real-Time Monitoring, and Precision Patient Selection

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

BostonGene’s AI-driven platform delivers deep immune and tumor insights that address core challenges in drug development: identifying predictive biomarkers, optimizing patient selection, and improving understanding of therapeutic resistance. By enabling blood-based, longitudinal profiling, BostonGene enhances cohort design, accelerates trial timelines, and strengthens regulatory submissions. BostonGene’s omnimodal platform combines high-resolution immune profiling with circulating-free RNA (cfRNA)-based tumor detection, trained on billions of data points across real-world trials. This enables accurate, dynamic prediction of response and resistance—especially in complex, heterogeneous tumors.

“We are honored that BioTech Breakthrough recognized us with ‘Overall Immunology Company of the Year.’ We saw how traditional methods were limiting the effective use of immune checkpoint inhibitors (ICIs), which, while transformative in cancer treatment, are only effective in a subset of patients. Our platform makes personalized treatment and response monitoring a reality from a single tube of blood,” said Andrew Feinberg, President and CEO of BostonGene. “The clinical impact is already clear. In head and neck cancer trials, our platform outperformed conventional biomarkers in predicting patient response from baseline blood. This platform not only enables personalized care—it empowers drug developers to make faster, smarter decisions grounded in real biology.”

The biotechnology sector is rapidly transforming the future of healthcare, agriculture, and life sciences—reshaping one of the world’s most critical and dynamic industries. From groundbreaking gene therapies and advanced biologics to precision medicine, sustainable biomanufacturing solutions, and more, biotechnology is driving greater innovation, efficiency, and global impact in improving human health and advancing scientific progress. The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 15 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.

“BostonGene’s minimally invasive approach enables biomarker discovery and real-time monitoring, enhancing patient selection and therapy response prediction. Traditional ICI biomarkers rely on tissue biopsies and offer limited predictive value. Crucially, single-site samples fail to capture tumor heterogeneity and dynamic changes,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “BostonGene improves patient care by preventing ineffective treatments, minimizing invasive procedures and enabling timely, informed therapy decisions. Physicians finally have a window into treatment response and resistance, while pharmaceutical companies benefit from enhanced trial efficiency, accelerated development and stronger regulatory evidence.”

About BostonGene Corporation

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Contacts

Media Contact:
BostonGene

Erin Keleher

+1-617-283-2285

Erin.Keleher@BostonGene.com